Switzerland· 73460001
Lysodren
A mitotane product, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Mitotane is registered in 15 of 19 countries.
Countries holding a registration under ATC L01XX23 (mitotane), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 10 of them publish a price we can compare per daily dose
Mitotane · ATC L01XX23
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01XX23
- ATC class
- Mitotane
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- August 1, 2026
Packs & prices · 1
1 priced- gtin7680573460017100 StkCHF 681.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
376 interactions on record for mitotane.
Graded by severity as the source publishes them — 193 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mitotane · interactions on record
376 records
- 193 severe
- 138 moderate
- 30 minor
- 15 info
Most severe, free to view
- RolapitantA04AD14severe
- NaloxegolA06AH03severe
- NaldemedineA06AH05severe
- EliglustatA16AX10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XX23
Mitotane, as other registers publish it.
- FinlandLysodrenEsteve Pharmaceuticals, S.A
- United StatesLysodrenESTEVE PHARMACEUTICALS, S.A.
- United StatesLysodrenHRA Pharma Rare Diseases
- PolandLysodrenHRA Pharma Rare Diseases
- DenmarkLysodrenEsteve Pharmaceuticals S.A.
- IcelandLysodrenEsteve Pharmaceuticals S.A.
- United StatesLysodrenESTEVE PHARMACEUTICALS, S.A.
- NorwayLysodrenEsteve Pharmaceuticals S.A
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d5946fd9-46a1-4fc5-a48a-6802e5906e7c GET /v1/drugs/d5946fd9-46a1-4fc5-a48a-6802e5906e7c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "mitotanum",
"valid_from": "2026-08-01",
"limitations": null,
"galenic_form": "Tabl 500 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2026-08-01",
"self_retention_pct": 10
}See everything about mitotane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.